Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133335 | 0.74 | — | — | |
| SCHEMBL10443473 | 0.74 | — | — | |
| SCHEMBL2390543 | 0.74 | — | — | |
| SCHEMBL1360791 | 0.72 | — | — | |
| SCHEMBL7301407 | 0.72 | — | — | |
| SCHEMBL8383315 | 0.67 | — | — | |
| SCHEMBL7092889 | 0.67 | ATR (0.33) | — | |
| SCHEMBL7347724 | 0.67 | — | — | |
| SCHEMBL425239 | 0.67 | — | — | |
| Bicarbonate SCHEMBL29184261 | 0.67 | TP53 (0.39) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407952-B2 | Reverse-turn mimetics and compositions and methods related thereto | MYRIAD GENETICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7405212-B2 | Helix mimetics and composition and methods related thereto | MYRIAD GENETICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7053214-B2 | β-sheet mimetics and composition and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060084653-A1 | Beta-sheet mimetics and composition and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1482941-A4 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-10 | — | — | US | disclosed |
| US-20050245528-A1 | substance P, integrin receptor antagonist; mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins; antiinflammatory agent; cell adhesion-mediated disease and central nervous system disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050222143-A1 | Helix mimetics and composition and methods related thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-10-06 | — | — | US | disclosed |
| US-6943157-B2 | Reverse-turn mimetics and composition and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6943167-B2 | Helix mimetics and composition and methods related thereto | MYRIAD GENETICS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1482941-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | Myriad Pharmaceuticals, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004035587-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003068237-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003030907-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003018587-A1 | HELIX MIMETICS AND COMPOSITION AND METHODS RELATED THERETO | MYRIAD GENETICS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| CN-1181720-A | Remotely programmable matrices with memories and uses thereof | IRORI (US) | 1998-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222143-A1 | Helix mimetics and composition and methods related thereto | BDKRB2, BDKRB1, NGLY1 | TP53 2411/4885 |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | TAC3, NTSR1, SCTR | TP53 2168/4885 |
| US-20050245528-A1 | substance P, integrin receptor antagonist; mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins; antiinflammatory agent; cell adhesion-mediated disease and central nervous system disorders | SELP, TACR1, SELPLG | TP53 3600/4885 |
| US-20060084653-A1 | Beta-sheet mimetics and composition and methods relating thereto | TPSAB1, TPSB2, TPSD1 | TP53 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.